David Cory, Eiger BioPharmaceuticals CEO (via MultiVu)

FDA re­jects Eiger's emer­gency use re­quest for re­pur­posed Covid-19 treat­ment

Eiger Bio­Phar­ma­ceu­ti­cals is no longer plan­ning to sub­mit an emer­gency use ap­pli­ca­tion to the FDA.

The Pa­lo Al­to, CA-based biotech had hoped to re­pur­pose its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.